ZOMETA® - Threat Of SREs From Bone Metastases Increases Treatments In Lung Cancer Extend Survival

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

About ZOMETA
Lung Cancer
Threat of SREs

Page

1 2

As new treatments extend survival, the threat of SREs increases

The median survival for patients with advanced lung cancer treated with
paclitaxel + carboplatin + bevacizumab is more than 1 year⁴
The median time to first SRE is only 1.2 months after diagnosis of metastasis
in patients with lung cancer⁵

Median time to first SRE vs median survival in advanced lung cancer^4,5

*Median survival of patients treated with paclitaxel + carboplatin + bevacizumab.

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

As new treatments extend survival, the threat of SREs increases

Median time to first SRE vs median survival in advanced lung cancer4,5

*Median survival of patients treated with paclitaxel + carboplatin + bevacizumab.

Median time to first SRE vs median survival in advanced lung cancer^4,5